Compare KELYA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | AVIR |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | United States |
| Employees | N/A | 56 |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 318.0M |
| IPO Year | N/A | 2020 |
| Metric | KELYA | AVIR |
|---|---|---|
| Price | $10.61 | $4.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $16.00 | $6.00 |
| AVG Volume (30 Days) | 424.7K | ★ 520.9K |
| Earning Date | 02-13-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,392,800,000.00 | N/A |
| Revenue This Year | $0.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.46 | N/A |
| 52 Week Low | $7.98 | $2.46 |
| 52 Week High | $15.11 | $4.34 |
| Indicator | KELYA | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 62.12 |
| Support Level | $9.84 | $3.75 |
| Resistance Level | $11.39 | $4.31 |
| Average True Range (ATR) | 0.39 | 0.24 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 59.14 | 76.51 |
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).